Sandoz Wins Incontinence IP Claim Against Astellas
Astellas has fended off efforts by two generic-drug makers to invalidate one of its U.K. patents for a treatment for overactive bladder syndrome but failed to persuade a judge that its...To view the full article, register now.
Already a subscriber? Click here to view full article